Last reviewed · How we verify
NCT04655872
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
Phase 1 trial testing [14C]TPN171H in Healthy Male Subjects in 6 participants. Completed in 27 January 2021.
27 January 2021
Quick facts
| Lead sponsor | Vigonvita Life Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 6 |
| Start date | 26 November 2020 |
| Primary completion | 27 January 2021 |
| Estimated completion | 27 January 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- [14C]TPN171H — full drug profile →
Conditions studied
- Healthy Male Subjects — all drugs for Healthy Male Subjects →
Sponsor
Vigonvita Life Sciences — full company profile →
Who can join
Adults 18 to 40, male only, with Healthy Male Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is objective to evaluate the in vivo absorption, excretion and biotransformation pathways of \[14C\]-TPN171H in Chinese male healthy volunteers, and to reveal the overall pharmacokinetic characteristics of TPN171H in human body, so as to provide basis for rational use of the drug.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacokinetics, mass balance, and metabolism of [<sup>14</sup>C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension.
He YF, Liu Y, Yu JH, Cheng H, et al · · 2023 · cited 10× · PMID 35676531 · DOI 10.1038/s41401-022-00922-6
Verify or expand the search:
- PubMed search for NCT04655872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Male Subjects
Currently open trials in the same condition.
- NCT07340476 — A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects · Phase 1 · active not recruiting
Other Vigonvita Life Sciences trials
Trials by the same sponsor.
- NCT07507838 — Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules · EARLY_PHASE1 · not yet recruiting
- NCT07302269 — Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT06749236 — A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension · Phase 1 · completed
- NCT06828887 — Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD · Phase 2 · recruiting
- NCT06504290 — Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04655872 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vigonvita Life Sciences
- Last refreshed: 25 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing